Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus

Blood

Volumn 116, Issue 13, 2010, Pages 2336-2344

  Zhang, Wei ^a   Li, Yong Sheng ^a   Nardi, Michael A ^a   Dang, Suying ^a   Yang, Jing ^a   Ji, Yong ^a   Li, Zongdong ^a   Karpatkin, Simon ^a   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; GLYCOPROTEIN IIIA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A11; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN LINKED FIRST KRINGLE PLASMINOGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; BRAIN HEMORRHAGE; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

EID: 77957694159     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-264358     Document Type: Article

References (30)

1. Nardi M, Tomlinson S, Greco MA, et al. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell. 2001;106(5):551-561. (Pubitemid 32879317)
2. Nardi M, Feinmark SJ, Hu L, et al. Complement-independent Ab-induced peroxide lysis of platelets requires 12-lipoxygenase and a platelet NADPH oxidase pathway. J Clin Invest. 2004;113(7):973-980. (Pubitemid 38544118)
3. Nardi MA, Gor Y, Feinmark SJ, et al. Platelet particle formation by anti GPIIIa49-66 Ab, Ca2+ ionophore A23187, and phorbol myristate acetate is induced by reactive oxygen species and inhibited by dexamethasone blockade of platelet phospholipase A2, 12-lipoxygenase, and NADPH oxidase. Blood. 2007;110(6):1989-1996.
4. Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood. 2005;106(2):572-576.
5. Li Z, Nardi MA, Li YS, et al. C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates, and protects against carotid artery occlusion and cerebral stroke. Blood. 2009;113(24):6051-6060.
6. Li Z, Nardi MA, Wu J, et al. Platelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin. J Biol Chem. 2008;283(6):3224-3230.
7. Choudhri TF, Hoh BL, Zerwes HG, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998;102(7):1301-1310.
8. Abumiya T, Fitridge R, Mazur C, et al. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke. 2000;31(6):1402-1409.
9. Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39(1):87-99.
10. Mandava P, Thiagarajan P, Kent TA. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. Drugs. 2008;68(8):1019-1028. (Pubitemid 351693672)
11. Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008;14(7):731-737.
12. Choi JH, Bateman BT, Mangla S, et al. Endovascular recanalization therapy in acute ischemic stroke. Stroke. 2006;37(2):419-424. (Pubitemid 43731998)
13. del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):2945-2948.
14. Quartermain D, Li YS, Jonas S. Acute enoxaparin treatment widens the therapeutic window for tPA in a mouse model of embolic stroke. Neurol Res. 2007;29(5):469-475.
15. Fleury V, Anglés-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochem. 1991;30(30):7630-7638.
16. Lamberski JA, Thompson NE, Burgess RR. Expression and purification of a single-chain variable fragment antibody derived from a polyolresponsive monoclonal antibody. Protein Expr Purif. 2006;47(1):82-92.
17. Chen P, Sun CX, Liu JN. A novel anti-platelet monoclonal antibody (3C7) specific for the complex of integrin alpha IIb beta3 inhibits platelet aggregation and adhesion. J Biol Chem. 2005;280(27):25403-25408.
18. Scholtzova H, Kascsak RJ, Bates KA, et al. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology. J Neurosci. 2009;29(6):1846-1854.
19. Sadowski M, Pankiewicz J, Scholtzova H, et al. Blocking the apolipoproteinE/amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice. Proc Natl Acad Sci U S A. 2006;103(49):18787-18792.
20. Nardi MA, Liu LX, Karpatkin S. GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia. Proc Natl Acad Sci U S A. 1997;94(14):7589-7594.
21. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation. 2002;106(3):379-385.
22. Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost. 2006;4(3):678-679.
23. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103(2):201-206. (Pubitemid 32095403)
24. Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol. 2000;36(5):1514-1519.
25. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des. 2004;10(14):1587-1596.
26. Bassler N, Loeffler C, Mangin P, et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol. 2007;27(3):e9-e15.
27. Tam SH, Sassoli PM, Jordan RE, et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v) beta3 integrins. Circulation. 1998;98(11):1085-1091.
28. Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100(25):2499-2506. (Pubitemid 30005113)
29. Leath CA III, Douglas JT, Curiel DT, et al. Single-chain antibodies: a therapeutic modality for cancer gene therapy. Int J Oncol. 2004;24(4):765-771.
30. Peter K, Graeber J, Kipriyanov S, et al. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation. 2000;101(10):1158-1164.